Results for tag: "Parsabiv"

Parsabiv (etelcalcetide) is a medication used to treat secondary hyperparathyroidism (SHPT) in adults with chronic kidney disease (CKD) on hemodialysis. It is a calcimimetic agent, meaning it works by activating the calcium-sensing receptor (CaSR) in the parathyroid gland, which helps to reduce the amount of parathyroid hormone (PTH) produced. This helps to reduce the risk of complications associated with SHPT, such as bone disease, vascular calcification, and cardiovascular disease. The Parsabiv market is part of the larger Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat a variety of conditions, such as diabetes, thyroid disorders, and obesity. The market is highly competitive, with a number of companies offering similar products. Some of the companies in the Parsabiv market include Amgen, Inc., Daiichi Sankyo, Inc., and Teva Pharmaceutical Industries Ltd. Show Less Read more